Loading...

Organovo Holdings

DB:4OR
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4OR
DB
$119M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
4OR Share Price and Events
7 Day Returns
3.3%
DB:4OR
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-5.4%
DB:4OR
-5.6%
DE Biotechs
-4.5%
DE Market
4OR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Organovo Holdings (4OR) 3.3% -7.6% 0.2% -5.4% -63.2% -77%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
Price Volatility
4OR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Organovo Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Organovo Holdings. This is due to cash flow or dividend data being unavailable. The share price is €0.913.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Organovo Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Organovo Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4OR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.24
NasdaqGM:ONVO Share Price ** NasdaqGM (2019-04-25) in USD $0.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Organovo Holdings.

DB:4OR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ONVO Share Price ÷ EPS (both in USD)

= 0.99 ÷ -0.24

-4.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organovo Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Organovo Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Organovo Holdings's expected growth come at a high price?
Raw Data
DB:4OR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-3.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Organovo Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Organovo Holdings's assets?
Raw Data
DB:4OR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.30
NasdaqGM:ONVO Share Price * NasdaqGM (2019-04-25) in USD $0.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:4OR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ONVO Share Price ÷ Book Value per Share (both in USD)

= 0.99 ÷ 0.30

3.26x

* Primary Listing of Organovo Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organovo Holdings is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Organovo Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Organovo Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Organovo Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-3.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Organovo Holdings expected to grow at an attractive rate?
  • Unable to compare Organovo Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Organovo Holdings's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Organovo Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4OR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4OR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -3.7%
DB:4OR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 45.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4OR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4OR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 40 1
2023-03-31 7 1
2022-03-31 5 1
2021-03-31 5 -29 2
2020-03-31 3 -29 3
2019-03-31 3 -27 3
DB:4OR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -21 -27
2018-09-30 4 -23 -28
2018-06-30 4 -25 -32
2018-03-31 5 -29 -35
2017-12-31 4 -30 -38
2017-09-30 4 -31 -40
2017-06-30 4 -31 -40
2017-03-31 4 -29 -38
2016-12-31 4 -29 -36
2016-09-30 3 -29 -37
2016-06-30 2 -32 -39
2016-03-31 1 -29 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Organovo Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Organovo Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4OR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Organovo Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4OR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 -0.21 -0.21 -0.21 1.00
2023-03-31 -0.34 -0.34 -0.34 1.00
2022-03-31 -0.28 -0.28 -0.28 1.00
2021-03-31 -0.25 -0.24 -0.26 2.00
2020-03-31 -0.25 -0.22 -0.27 3.00
2019-03-31 -0.24 -0.23 -0.24 3.00
DB:4OR Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.24
2018-09-30 -0.26
2018-06-30 -0.29
2018-03-31 -0.32
2017-12-31 -0.36
2017-09-30 -0.38
2017-06-30 -0.39
2017-03-31 -0.39
2016-12-31 -0.38
2016-09-30 -0.40
2016-06-30 -0.42
2016-03-31 -0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Organovo Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Organovo Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Organovo Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Organovo Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Organovo Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Organovo Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Organovo Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Organovo Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Organovo Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Organovo Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4OR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.52 -27.10 16.23
2018-09-30 3.89 -28.49 17.70
2018-06-30 4.30 -32.12 19.80
2018-03-31 4.60 -34.80 20.89
2017-12-31 4.31 -38.01 22.24
2017-09-30 4.31 -39.80 22.92
2017-06-30 4.33 -39.78 23.10
2017-03-31 4.23 -38.45 22.30
2016-12-31 3.97 -36.16 20.96
2016-09-30 3.14 -37.04 21.62
2016-06-30 2.07 -38.85 22.55
2016-03-31 1.48 -38.58 22.12
2015-12-31 1.20 -38.00 22.28
2015-09-30 1.03 -34.54 19.94
2015-06-30 0.78 -32.14 18.87
2015-03-31 0.57 -30.08 17.95
2014-12-31 0.42 -28.77 17.66
2014-09-30 0.40 -26.98 16.17
2014-06-30 0.37 -28.51 14.39
2014-03-31 0.38 -25.85 13.05
2013-12-31 0.48 -35.49 11.53
2013-09-30 0.69 -39.84 11.29
2013-06-30 1.14 9.02 10.27
2013-03-31 1.29 -22.59 8.97
2012-12-31 1.20 -43.55 7.08
2012-09-30 1.21 -36.49 5.51 1.42
2012-06-30 0.97 -75.77 3.08 1.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Organovo Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Organovo Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Organovo Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Organovo Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Organovo Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Organovo Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Organovo Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Organovo Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Organovo Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Organovo Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Organovo Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Organovo Holdings Company Filings, last reported 3 months ago.

DB:4OR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 35.68 0.00 35.22
2018-09-30 38.87 0.00 37.36
2018-06-30 41.36 0.00 39.61
2018-03-31 44.59 0.00 43.73
2017-12-31 48.60 0.00 47.34
2017-09-30 52.06 0.00 50.73
2017-06-30 57.27 0.00 54.97
2017-03-31 62.36 0.00 62.75
2016-12-31 70.90 0.00 70.00
2016-09-30 52.49 0.00 51.72
2016-06-30 54.84 0.00 53.54
2016-03-31 62.18 0.00 62.09
2015-12-31 69.04 0.00 70.03
2015-09-30 76.15 0.00 76.86
2015-06-30 85.32 0.00 86.00
2015-03-31 48.70 0.01 50.14
2014-12-31 48.31 0.01 50.03
2014-09-30 53.43 0.01 54.39
2014-06-30 43.82 0.01 44.90
2014-03-31 48.28 0.02 48.17
2013-12-31 48.70 0.02 49.82
2013-09-30 51.94 0.02 53.36
2013-06-30 6.91 0.02 12.85
2013-03-31 8.97 0.03 15.63
2012-12-31 -5.30 0.03 14.82
2012-09-30 -27.42 0.03 7.68
2012-06-30 -71.76 0.00 8.47
  • Organovo Holdings has no debt.
  • Organovo Holdings had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Organovo Holdings has sufficient cash runway for 1.7 years based on current free cash flow.
  • Organovo Holdings has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -9.2% each year.
X
Financial health checks
We assess Organovo Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Organovo Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Organovo Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Organovo Holdings dividends.
If you bought €2,000 of Organovo Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Organovo Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Organovo Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4OR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4OR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Organovo Holdings has not reported any payouts.
  • Unable to verify if Organovo Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Organovo Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Organovo Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Organovo Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Organovo Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Organovo Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Organovo Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Taylor Crouch
COMPENSATION $4,622,438
AGE 58
TENURE AS CEO 2 years
CEO Bio

Mr. Taylor J. Crouch has been Chief Executive Officer and President of Organovo Holdings, Inc. since April 25, 2017. Mr. Crouch served as Chief Executive Officer of eStudySite, Inc. until April 2017. Mr. Crouch has 25 years of drug development and commercialization experience spanning large pharmaceutical companies, biotech and the CRO industry. Mr.Crouch served as Senior Vice President of Operations & Supply Operations and President of International of Ligand Pharmaceuticals Incorporated since May 2005. Prior to joining Ligand in May 2005, Mr. Crouch served as President and Chief Operating Officer of Discovery Partners International Inc. from July 2002 to January 2005. From April 1999 to April 2002, he served as President and Chief Executive Officer of Variagenics Inc. From January 1991 to March 1999, he served as the Senior Vice President of Worldwide Marketing and Strategic Development of PAREXEL International Corp. He held various positions for over ten years with Schering-Plough International and Pfizer. He has been Director of Organovo Holdings, Inc. since April 25, 2017. He has been Director of BIOCOM, Inc. since May 31, 2018. He served as a Director of Bruker AXS, Inc. since November 2000. He served as an Independent Director of Bruker Corporation from July 2003 to May 16, 2007. From April 1999 to April 2002, he served as a Director of Variagenics, Inc. Mr. Crouch has a B.S. in Chemical Engineering, cum laude, from Princeton University and an M.B.A. in International Finance and Marketing from the University of Chicago.

CEO Compensation
  • Insufficient data for Taylor to compare compensation growth.
  • Taylor's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Organovo Holdings management team in years:

2.3
Average Tenure
55.5
Average Age
  • The tenure for the Organovo Holdings management team is about average.
Management Team

Taylor Crouch

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
58
TENURE
2 yrs

Craig Kussman

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
59
TENURE
2.7 yrs

Jennifer Bush

TITLE
Senior VP
COMPENSATION
$1M
AGE
43

Paul Gallant

TITLE
General Manager
COMPENSATION
$789K
AGE
53
TENURE
3.7 yrs

Steve Kunszabo

TITLE
VP of Investor Relations & Corporate Communications

Steve Hughes

TITLE
Chief Medical Officer
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Organovo Holdings board of directors in years:

5.8
Average Tenure
63
Average Age
  • The tenure for the Organovo Holdings board of directors is about average.
Board of Directors

Kirk Malloy

TITLE
Chairman & Lead Director
COMPENSATION
$168K
AGE
51

Taylor Crouch

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
58
TENURE
1.9 yrs

Bob Baltera

TITLE
Director
COMPENSATION
$131K
AGE
53
TENURE
9.5 yrs

James Glover

TITLE
Director
COMPENSATION
$137K
AGE
68
TENURE
6.8 yrs

David Mooney

TITLE
Scientific Advisor

Glenn Prestwich

TITLE
Scientific Advisor

Gordana Vunjak-Novakovic

TITLE
Scientific Advisor

K. Kent

TITLE
Scientific Advisor

Tamar Howson

TITLE
Independent Director
COMPENSATION
$121K
AGE
69
TENURE
5.8 yrs

Mark Kessel

TITLE
Director
COMPENSATION
$112K
AGE
76
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Organovo Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Organovo Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

Details
Name: Organovo Holdings, Inc.
4OR
Exchange: DB
Founded: 2007
$107,281,122
119,493,341
Website: http://www.organovo.com
Address: Organovo Holdings, Inc.
6275 Nancy Ridge Drive,
Suite 110,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ONVO Common Stock Nasdaq Global Market US USD 09. Feb 2012
DB 4OR Common Stock Deutsche Boerse AG DE EUR 09. Feb 2012
LSE 0R02 Common Stock London Stock Exchange GB USD 09. Feb 2012
Number of employees
Current staff
Staff numbers
70
Organovo Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:14
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.